Navigation Links
Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
Date:3/26/2008

-- Currently enrolling patients in U.S. Phase II clinical trial for cocaine

addiction -- Expect to initiate U.S. Phase II clinical trial for methamphetamine

addiction in second quarter of 2008

CORAL GABLES, Fla., March 26 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction, today reported financial results for the fourth quarter and year ended December 31, 2007.

Commenting on the year, Patrick J. McEnany, Chief Executive Officer of Catalyst Pharmaceutical Partners, noted, "Operationally, 2007 was an important year for Catalyst, during which time we achieved several key milestones. Most notably, we developed CPP-109, Catalyst's finished dosage form of vigabatrin, which is now being used in our first U.S. Phase II clinical trial. We also reported successful results of the use of vigabatrin to treat cocaine addiction, from a New York University, investigator-sponsored, double-blind, placebo-controlled Phase II trial in Mexico that was partially supported by Catalyst. That trial confirmed the positive results of the prior two Mexican human pilot studies."

Mr. McEnany continued, "In preparation for our clinical development efforts, we have also strengthened our management team with two key appointments. Steven R. Miller, Ph.D. joined the Company as Vice President of Pharmaceutical Development and Project Management and Patrick Kenny came on board as Director - Corporate Clinical Compliance."

"During 2007, we expanded our Scientific Advisory Board with two new members; Dr. Thomas Kosten, the Waggo
'/>"/>

SOURCE Catalyst Pharmaceutical Partners
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... , Aug. 27, 2014 Higher ... insurance are fuelling the demand for medical devices ... rise of medical tourism, the inflow of patients ... The market will continue its steady ascent as ... age-related and non-communicable diseases, compelling significant investments in ...
(Date:8/26/2014)... plc (NYSE: ACT ), a leading global specialty ... and President of Actavis, will provide an overview and update ... Conference 2014 in New York, NY . ... presentation will take place on Tuesday, September 9, 2014 at ... 109 East 42 nd Street, New York, ...
(Date:8/26/2014)... -- Research and Markets  has announced the addition ... report to their offering. Intranasal drug ... administration of drugs for the treatment of local diseases ... and non-allergic rhinitis and sinusitis. The nose is considered ... and systematic drug delivery. Continuous technological ...
Breaking Medicine Technology:Frost & Sullivan: Change in Demographics and Surge in Domestic Manufacturing Drive Asia-Pacific Medical Devices Market 2Frost & Sullivan: Change in Demographics and Surge in Domestic Manufacturing Drive Asia-Pacific Medical Devices Market 3Frost & Sullivan: Change in Demographics and Surge in Domestic Manufacturing Drive Asia-Pacific Medical Devices Market 4Actavis to Present at Morgan Stanley Global Healthcare Conference 2014 2Global Intranasal Drug Delivery Market 2014-2018: Key Vendors are Becton, Dickinson and Company, GlaxoSmithKline, Johnson & Johnson and Novartis 2Global Intranasal Drug Delivery Market 2014-2018: Key Vendors are Becton, Dickinson and Company, GlaxoSmithKline, Johnson & Johnson and Novartis 3
... Inc. (Nasdaq: BNVI ) announced today the publication ... of tamoxifen on estrogen receptor beta (ERb) gene regulation. ... in Molecular and Cellular Endocrinology, demonstrate that tamoxifen inhibits ... breast cancer cell proliferation. , "Tamoxifen has been ...
... , BEIJING, Oct. 20 /PRNewswire-Asia-FirstCall/ ... "the Company") a leading manufacturer, developer,and distributor of Shengmingsu ... of China (PRC), today announced that the Company consummated,the ... of October,16, 2009. , Yongye ...
Cached Medicine Technology:Bionovo Announces Publication of Data on Potential Increase in Breast Cancer Risk Due to the Inhibitory Effect of Tamoxifen Treatment on Estrogen Receptor Beta 2Bionovo Announces Publication of Data on Potential Increase in Breast Cancer Risk Due to the Inhibitory Effect of Tamoxifen Treatment on Estrogen Receptor Beta 3Yongye International Announces Completion of Restructuring 2Yongye International Announces Completion of Restructuring 3
(Date:8/27/2014)... Lighthouse Payment Services Inc ., ... it will exhibit its image-based lockbox services at the ... convention in beautiful Lake Placid, New York from ... be held at the Lake Placid Convention Center and ... options in addition to a variety of vendors exhibiting ...
(Date:8/27/2014)... CT (PRWEB) August 27, 2014 Do brands ... International is about to shed some light on the topic ... to members of the Brand Activation Association and ... marketing company polled hundreds of consumers to learn what types ... biggest impact on influencing a potential buying decision. While the ...
(Date:8/27/2014)... Beginning in September, K9 Dog Park ... an interactive, fun way for daycare dogs to learn and ... Dog Park Doggy Daycare clients who bring their dogs into ... Clients will be able to watch their dogs compete through ... compete in D.O.G. will win prizes as will the trainers ...
(Date:8/27/2014)... one of the leading purveyors of real and synthetic hair wigs, ... all its products, for the coming Labor Day. , People searching ... hair products in two ways: when they spend more than ... code LABOR10; while when they spend more than $299, they can ... coupon code is needed when securely checkout, there are about 50 ...
(Date:8/27/2014)... They say knowledge is power, and a new UCLA study ... to men making the best decisions about how to treat ... aren,t well educated about their disease have a much more ... that could negatively impact the quality of their care and ... wake-up call for physicians, who can use the findings to ...
Breaking Medicine News(10 mins):Health News:CRN Set To Release Poll Results On What Marketing Tactics Prompt Consumers To Buy 2Health News:K9 Dog Park Announces Launch Of Daycare Olympic Games – D.O.G. 2Health News:K9 Dog Park Announces Launch Of Daycare Olympic Games – D.O.G. 3Health News:K9 Dog Park Announces Launch Of Daycare Olympic Games – D.O.G. 4Health News:UniWigs Is Offering A Big Sale for Labor Day on All Its Products 2Health News:Men who are uneducated about their prostate cancer have difficulty making good treatment choices 2Health News:Men who are uneducated about their prostate cancer have difficulty making good treatment choices 3
... you take to lower cholesterol may help protect against ... followed more than 7,500 women ages 65 years and ... study show more than 3 percent of women who ... 2.1 percent of women who used statin cholesterol-lowering drugs ...
... in a migraine medication study who cheated and took the ... a big favor.// ,A new study shows the medication ... rather than waiting until pain is moderate to severe, as ... on the use of drugs known as serotonin agonists for ...
... answer when it comes to children losing weight. The study ... may actually promote weight gain.,// ,Obesity is a serious ... United States. During the past two decades, the prevalence of ... percent. Dieting to lose weight is common among adolescent girls ...
... protect them against severe strains of the bacterium Streptococcus ... according to a new study.,// ,Researchers from Harvard ... in 16 diverse communities throughout Massachusetts. Results of the ... strain of S. pneumoniae -- a bacterium that causes ...
... options, but new research shows there may be a way to ... among men in the United States -- affecting nearly 200,000 men ... outlived all his family members. "My mom died at 56. My ... brother at 58, and my next one at 67," he tells ...
... the importance of weight control throughout life to control ... low socio-economic status during childhood can also contribute to ... suggested the negative effect of birthweight on systolic blood ... age. Researchers from Royal Free and University College of ...
Cached Medicine News:
... with ease of use make the OM-5 ... Ideal for office or hospital-based urodynamics, the ... cystometry, leak point pressure, or urethral pressure ... make the OM-5 flexible enough to meet ...
Windows-Based Urodynamics for Fast and Straightforward. Testing For Clinics Where Logic and Efficiency are at a Premium...
... The Corkscrew FT II (fully threaded) ... anchor designed to be inserted flush with ... strength and anchor stability. The full thread ... suture anchors with protruding eyelets. Especially advantageous ...
... (fully threaded) is a 5.5 mm diameter ... flush with the cortical bone surface to ... fully threaded design substantially improves pull-out strength ... The fully threaded design prevents anchor pull-back ...
Medicine Products: